Search results
-
2025
BOS-318 treatment enhances elexacaftor–tezacaftor–ivacaftor-mediated improvements in airway hydration and mucociliary transport
Douglas, L. E. J., Reihill, J. A. & Martin, S. L., Jan 2025, In: ERJ Open Research. 11, 1, 8 p., 00445-2024.Research output: Contribution to journal › Article › peer-review
Open AccessFile34 Downloads (Pure) -
2023
Highly selective furin inhibition as a therapeutic approach for chronic obstructive pulmonary disease
Douglas, L., Reihill, J., Odrljin, T. & Martin, L., 01 Nov 2023, In: European Respiratory Journal. 62, suppl 67, PA1868.Research output: Contribution to journal › Meeting abstract › peer-review
-
Putting the CAP on ENaC: The role of serine proteases in the regulation of airways hydration and mucociliary clearance in chronic airways diseases.
Martin, L., 02 Nov 2023.Research output: Contribution to conference › Paper › peer-review
-
2022
A highly selective, cell-permeable furin inhibitor BOS-318 rescues key features of cystic fibrosis airways disease
Douglas, L. E. J., Reihill, J. A., Ho, M. W. Y., Axten, J. M., Campobasso, N., Schneck, J. L., Rendina, A. R., Wilcoxen, K. M. & Martin, S. L., 16 Jun 2022, In: Cell Chemical Biology. 29, 6, p. P947-957.E8Research output: Contribution to journal › Article › peer-review
Open AccessFile22 Link opens in a new tab Citations (Scopus)151 Downloads (Pure) -
2021
Highly selective, first-in-class furin inhibitor BOS-318 inhibits ENaC and restores airway hydration in cystic fibrosis
Douglas, L., Reihill, J., Ho, M., Axten, J., Campobasso, N., Wilcoxen, K. & Martin, S., 01 Nov 2021, In: Journal of Cystic Fibrosis. 20, Supplement 2, p. S185 1 p., 391.Research output: Contribution to journal › Meeting abstract › peer-review